1
Roger D Tung, Mark A Murcko, Govinda R Bhisetti: Sulfonamide inhibitors of aspartyl protease. Vertex Pharmaceuticals Incorporated, James F Haley Jr, Jeffrey D Hsi, Fish & Neave, December 17, 1996: US05585397 (109 worldwide citation)

The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to phar ...


2
Roger D Tung, Scott L Harbeson, David D Deininger, Mark A Murcko, Govinda R Bhisetti, Luc J Farmer: Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. Vertex Pharmaceuticals Incorporated, James F Haley, Lisa A Dixon, Fish & Neave, July 24, 2001: US06265380 (85 worldwide citation)

The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhi ...


3
Guy W Bemis, Julian M C Golec, David J Lauffer, Michael D Mullican, Mark A Murcko: Inhibitors of interleukin-1.beta. converting enzyme. Vertex Pharmaceuticals, James F Haley Jr, Lisa A Dixon, Fish & Neave, May 26, 1998: US05756466 (72 worldwide citation)

The present invention relates to novel classes of compounds which are inhibitors of interleukin-1.beta. converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising ...


4
Guy W Bemis, Julian M C Golec, David J Lauffer, Michael D Mullican, Mark A Murcko, David J Livingston: Inhibitors of interleukin-1.beta. converting enzyme. Vertex Pharmaceuticals Incorporated, James F Haley Jr, Lisa A Dixon, Fish & Neave, December 8, 1998: US05847135 (68 worldwide citation)

The present invention relates to novel classes of compounds which are inhibitors of interleukin-1.beta. converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising ...


5
Guy W Bemis, Julian M C Golec, David J Lauffer, Michael D Mullican, Mark A Murcko, David J Livingston: Inhibitors of interleukin-1.beta. converting enzyme. Vertex Pharmaceuticals, James F Haley Jr, Lisa A Dixon, Fish & Neave, August 12, 1997: US05656627 (66 worldwide citation)

The present invention relates to novel classes of compounds which are inhibitors of interleukin-1.beta. converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising ...


6
Roger D Tung, Scott L Harbeson, David D Deininger, Mark A Murcko, Govinda R Bhisetti, Luc J Farmer: Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. Vertex Pharmaceuticals Incorporated, James F Haley Jr, Kyumin K Lee, Fish & Neave, September 9, 2003: US06617309 (65 worldwide citation)

The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhi ...


7
Guy W Bemis, Julian M C Golec, David J Lauffer, Michael D Mullican, Mark A Murcko, David J Livingston: Inhibitors of interleukin-1.beta. converting enzyme. Vertex Pharmaceuticals, James F Haley Jr, Lisa A Dixon, Fish & Neave, February 10, 1998: US05716929 (54 worldwide citation)

The present invention relates to novel classes of compounds which are inhibitors of interleukin-1.beta. converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising ...


8
Roger D Tung, Scott L Harbeson, David D Deininger, Mark A Murcko, Govinda R Bhisetti, Luc J Farmer: Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. Vertex Pharmaceuticals Incorporated, Ropes & Gray, James F Haley Jr, David A Roise, June 17, 2008: US07388017 (49 worldwide citation)

The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhi ...


9
Mark James Batchelor, David Bebbington, Guy W Bemis, Wolf Herman Fridman, Roger John Gillespie, Julian M C Golec, David J Lauffer, David J Livingston, Saroop Singh Matharu, Michael D Mullican, Mark A Murcko, Robert Murdoch, Robert E Zelle: Inhibitors of interleukin-1.beta. converting enzyme. Vertex Pharmaceuticals Incorporated, James F Haley Jr, Lisa A Dixon, Fish & Neave, February 23, 1999: US05874424 (48 worldwide citation)

The present invention relates to novel classes of compounds which are inhibitors of interleukin-1.beta. converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising ...


10
Janos Pitlik, Kevin M Cottrell, Luc J Farmer, Robert B Perni, Lawrence F Courtney, John H van Drie, Mark A Murcko: Inhibitors of serine proteases, particularly HCV NS3-NS4A protease. Vertex Pharmaceuticals Incorporated, Susan C Kelly, Lisa A Dixon, September 25, 2007: US07273885 (41 worldwide citation)

The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to ...